Menu Search
Equities

Advanced Health Intelligence Ltd

MYZQF:PKC

Advanced Health Intelligence Ltd

Actions
  • Price (USD)0.005
  • Today's Change0.00 / 0.00%
  • Shares traded21.27k
  • 1 Year change-96.67%
  • Beta--
Data delayed at least 15 minutes, as of Jun 14 2024 17:18 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Advanced Health Intelligence Limited is an Australia-based company that provides biometric-derived digital healthcare solutions. The Company’s products include Biometric Health Assessment (BHA), FaceScan, and BodyScan. Its BHA delivers preventative healthcare measures and refines risk stratification across populations. Its comprehensive insights cover a range of health vitals and risk predictions, allowing its partners to guide individuals into personalized stepped-care pathways. This includes connecting high-risk individuals to traditional primary care, telehealth, or e-health programs. FaceScan estimates vital signs and predicts the risk of chronic disease on a smartphone or Web browser. FaceScan provides estimated readings on heart rate, respiration rate, blood pressure and more in 30 seconds or less. BodyScan is optimized to run on-device using only a smartphone, to deliver accurate body dimension and composition estimates in 60 seconds or less.

  • Revenue in AUD (TTM)2.42m
  • Net income in AUD-16.66m
  • Incorporated2014
  • Employees--
  • Location
    Advanced Health Intelligence LtdUnit 5, 71-73 South Perth EsplanadePERTH 6151AustraliaAUS
  • Phone+61 89316-9100
  • Fax+61 89315-5475
  • Websitehttps://www.ahi.tech/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.